Macquarie Group’s ICU Medical ICUI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-285,791
Closed -$34.3M 1150
2025
Q3
$34.3M Buy
285,791
+6,274
+2% +$795K 0.04% 523
2025
Q2
$36.9M Buy
279,517
+23,705
+9% +$3.21M 0.05% 492
2025
Q1
$35.5M Buy
255,812
+26,764
+12% +$4.15M 0.04% 494
2024
Q4
$35.5M Buy
+229,048
New +$38.7M 0.04% 496
2022
Q4
Sell
-328
Closed -$98K 1934
2022
Q3
$98K Sell
328
-472
-59% -$78.5K ﹤0.01% 1767
2022
Q2
$132K Buy
800
+152
+23% +$29.3K ﹤0.01% 1800
2022
Q1
$144K Hold
648
﹤0.01% 1864
2021
Q4
$154K Sell
648
-87
-12% -$20.3K ﹤0.01% 1823
2021
Q3
$172K Hold
735
﹤0.01% 1833
2021
Q2
$151K Hold
735
﹤0.01% 1852
2021
Q1
$151K Sell
735
-193
-21% -$40.8K ﹤0.01% 1790
2020
Q4
$199K Hold
928
﹤0.01% 1666
2020
Q3
$170K Hold
928
﹤0.01% 1651
2020
Q2
$171K Buy
928
+328
+55% +$65.2K ﹤0.01% 1595
2020
Q1
$121K Hold
600
﹤0.01% 1583
2019
Q4
$112K Buy
+600
New +$103K ﹤0.01% 1755
2019
Q1
Sell
-100
Closed -$23K 1833
2018
Q4
$23K Sell
100
-200
-67% -$49.3K ﹤0.01% 1764
2018
Q3
$85K Sell
300
-1,100
-79% -$322K ﹤0.01% 1618
2018
Q2
$411K Buy
+1,400
New +$383K ﹤0.01% 1427

Other funds holding ICUI

Macquarie Group's ICUI Position: Q4 2025 in Review

Macquarie Group sold out of ICU Medical (ICUI) in Q4 2025, closing a stake of 285,791 shares — an estimated $34.3M sold.

Macquarie Group first reported a position in ICUI in Q2 2018 and held it in 19 quarters. The position peaked at $36.9M in Q2 2025. 291 funds tracked by Wall St. Rank hold ICUI as of Q4 2025.

  • Macquarie Group reported no remaining ICU Medical position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 285,791 ICU Medical shares in Q4 2025, an estimated $34.3M.
  • Macquarie Group first reported a position in ICU Medical in Q2 2018 and held it in 19 quarters.
  • Macquarie Group's ICU Medical position peaked at $36.9M in Q2 2025.
  • 291 funds tracked by Wall St. Rank held ICU Medical as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.